Tirzepatide is the most effective FDA-approved weight loss medication currently available — producing results that rival bariatric surgery in clinical trials. At Juvenis Medical, we prescribe it with the metabolic context it deserves.
Activates both GIP and GLP-1 receptors. GIP receptor activation amplifies insulin secretion and has additional effects on adipose tissue metabolism. The dual action produces consistently larger weight loss in clinical comparisons. Average loss: ~21% body weight at maximum dose.
Activates GLP-1 receptors only. Highly effective — the best-studied GLP-1 agonist with an excellent safety record. Average loss: ~15% body weight at maximum dose. Some patients respond exceptionally well to semaglutide and don't require tirzepatide's dual mechanism.
Both are excellent options. We evaluate your metabolic profile and weight history to recommend the best fit.
Review your weight history, health conditions, previous treatments, and goals. Dr. Paul recommends tirzepatide vs. semaglutide based on your specific profile.
Comprehensive blood work including thyroid, fasting insulin, HbA1c, hormone panel, lipids, and inflammatory markers. Weight loss outcomes improve significantly when underlying metabolic issues are addressed simultaneously.
Tirzepatide via compounded injectable, dose-escalated over 12–16 weeks. Combined with hormone optimization, metabolic peptides, or nutrient support based on your lab findings.
Regular follow-up labs assess your metabolic response and confirm safety. Protocol adjusted as needed. Most patients remain on tirzepatide for 6–12+ months to achieve and consolidate weight loss goals.
Tirzepatide is a once-weekly injectable that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, it is the most effective weight loss medication in clinical trials to date.
Same active molecule, prepared by a licensed compounding pharmacy. Allows for flexible dosing, lower cost, and the same therapeutic mechanism as the brand-name products.
Yes. Juvenis Medical prescribes compounded tirzepatide to patients in all 50 states via telehealth, with a complete metabolic evaluation included in the process.
Like semaglutide, the primary side effects are GI-related: nausea, constipation, and diarrhea — particularly during dose escalation. Starting at low doses and titrating slowly reduces these significantly. Most patients find side effects manageable and diminishing over time.
Both are excellent. Tirzepatide has shown greater average weight loss in trials, but individual responses vary. Some patients do exceptionally well on semaglutide. We'll evaluate your health history, metabolic labs, and goals to recommend the right starting point — and adjust if needed.
Some weight regain is common after discontinuation — which is why we address the underlying metabolic factors (hormones, insulin resistance, thyroid) throughout your protocol. The goal is sustainable metabolic health, not medication dependency.
Tirzepatide available via telehealth nationwide — with the metabolic evaluation that makes results stick. Free 15-minute consultation to start.
Book Free Consultation →